Li Mo,Wang Haiwei,Wang Lijuan,et al.The present and progress of common drug therapy in treating senile osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2019,(06):365-369.[doi:10.3877/cma.j.issn.2096-0263.2019.06.011]





The present and progress of common drug therapy in treating senile osteoporosis
130041 长春,吉林大学第二医院内分泌科1,骨科2
Li Mo1 Wang Haiwei1 Wang Lijuan1 Xiao Jianlin2 Gao Zhongli2 Cai Hanqing1
1Department of Endocrinology, 2Department of Orthopaedics, the Second Hospital of Jilin University, Changchun 130041, China
骨质疏松症 药物治疗 双膦酸盐 甲状旁腺素
Osteoporosis Drug therapy Bisophosphonates Parathyroid hormone
Osteoporosis is a very common disease among elderly people but still no effective therapy to cure. Drug therapy as the prevent treatment in osteoporosis has been proved valuable in releasing the clinical symptom and prevent the progress of fracture. With the increasing variety of osteoporosis drugs, the comprehension of the effect and side effect of drugs are growing. The laboratory and clinical studies of osteoporosis were reviewed, and the efficacy and safety of drug were summarized in this article, hopefully it can provide theoretical basis for clinical treatment of osteoporosis.


1 Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures [J]. J Bone Miner Res, 2005, 20(7): 1185-1194.
2 Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) [J]. Arch Osteoporos, 2011, 6: 59-155.
3 张智海, 张智若, 刘忠厚, 等. 中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究 [J]. 中国骨质疏松杂志, 2016, 22(1): 1-8.
4 Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease [J]. Endocr Rev, 1986, 7(4): 379-408.
5 Cosman F, De Beur SJ, Leboff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis [J]. Osteoporos Int, 2014, 25(10): 2359-2381.
6 Holick MF. Vitamin D deficiency [J]. N Engl J Med, 2007, 357(3): 266-281.
7 Larsen ER, Mosekilde L, Foldspang A. Vitamin D and Calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: A pragmatic population-based 3-year intervention study [J]. J Bone Miner Res, 2004, 19(3): 370-378.
8 Langdahl BL, Harsløf T. Medical treatment of osteoporotic vertebral fractures [J]. Ther Adv Musculoskelet Dis, 2011, 3(1): 17-29.
9 Fleisch H, Russell RG, Bisaz S, et al. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution [J]. Calcif Tissue Res, 1968, 2(1): Suppl:10-Suppl10a.
10 Reitsma PH, Teitelbaum SL, Bijvoet OL, et al. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro [J]. J Clin Invest, 1982, 70(5): 927-933.
11 张禄锴, 马剑雄, 李风波, 等. 双膦酸盐类药物治疗骨质疏松症的研究进展 [J]. 中华老年骨科与康复电子杂志, 2017, 3(3): 184-187.
12 Paskins Z, Warburton L. Bisphosphonates beyond five years [J]. BMJ, 2016, 352: i264.
13 Blum L, Cummings K, Goulet JA, et al. Atypical femur fractures in patients receiving bisphosphonate therapy: etiology and management [J]. Eur J Orthop Surg Traumatol, 2016, 26(4): 371-377.
14 Schilcher J, Koeppen V, Aspenberg P, et al. Risk of atypical femoral fracture during and after bisphosphonate use [J]. N Engl J Med, 2014, 371(10): 974-976.
15 Bonomi M, Nortilli R, Molino A, et al. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis [J]. Med Oncol, 2010, 27(2): 224-229.
16 Lam J. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand speci city [J]. J Clin Invest, 2001, 108(7): 971-979.
17 Rossini M, Adami G, Adami S, et al. Safety issues and adverse reactions with osteoporosis management [J]. Expert Opin Drug Saf, 2016, 15(3): 321-332.
18 Lacey DL, Boyle WJ, Simonet W, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab [J]. Nat Rev Drug Discov, 2012, 11(5): 401-U150.
19 Papapoulos S. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis:results from the FREEDOM Extension study [J]. Osteoporos Int, 2015, 26(12): 2773-2783.
20 Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis [J]. N Engl J Med, 2009, 361(8): 756-765.
21 Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [J]. JAMA, 1999, 281(23): 2189–2197.
22 Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density,serum cholesterol concentrations,and uterine endometrium in postmenopausal women [J]. N Engl J Med, 1997, 337(23): 1641–1647.
23 Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: Multiple outcomes of raloxifene evaluation [J]. Obstet Gynecol, 2004, 104(4): 837-844.
24 Malozowski S. Lasofoxifene for postmenopausal women with osteoporosis [J]. N Engl J Med, 2010, 362(23): 2227.
25 Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis [J]. N Engl J Med, 2001, 344(19): 1434-1441.
26 Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis [J]. N Engl J Med, 2007, 357(20): 2028-2039.
27 Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis a randomized clinical trial [J]. JAMA, 2016, 316(7): 722-733.
28 Meunier PJ, Roux C, Seeman E, et al. The effects of Strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis [J]. N Engl J Med, 2004, 350(5): 459-468.
29 Bonnelye E, Chabadel A, Saltel F, et al. Dual effect of Strontium ranelate: Stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro [J]. Bone, 2008, 42(1): 129-138.
30 Marie PJ. Optimizing bone metabolism in osteoporosis:insight into the pharmacologic profile of Strontium ranelate [J]. Osteoporos Int, 2003, 14(3): 9-12.
31 Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert [J]. Osteoporos Int, 2008, 19(12): 1811-1812.
32 Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database [J]. Osteoporos In, 2010, 21(7): 1181-1187.
33 Jiang Y, Zhang ZL, Zhang ZL, et al. Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial [J]. Clin Interv Aging, 2014, 9: 121-127.
34 韩阳, 李傲航, 叶卫丰. 2型糖尿病并发骨质疏松与NLR、RDW和MPV的关系 [J]. 临床和实验医学杂志, 2017, 16(17): 1734-1736.
35 Mahdiniae DA, Menaquinone-7 OA. (vitamin K2): a new perspective [J]. World J Microbiol Biotechnol, 2017, 33(1): 2.
36 Kodama Y, Okamoto Y, Kubota T, et al. Effectiveness of vitamin K2 on osteoporosis in adults with cerebral palsy [J]. Brain Dev, 2017, 39(10): 846-850.
37 Xu T, Wang L, Tao Y, et al. The function of naringin in inducing secretion of osteoprotegerin and inhibiting formation of osteoclasts [J]. Evid Based Complement Alternat Med, 2016: 8981650.
38 Zhu HM, Qin L, Garnero P, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis [J]. Bone, 2010, 47(3): S457-S458.
39 Liu M, Zhong C, He RX, et al. Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis [J]. Chin Med J(Engl), 2012, 125(10): 1784-1789.
40 Ouyang L, Zhang QF, Ruan XZ, et al. Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo [J]. Exp Ther Med, 2014, 7(6): 1687-1690.
41 Shuai B, Shen L, Zhu R, et al. Effect of Qing’e formula on the in vitro differentiation of bone marrow-derived mesenchymal stem cells from proximal femurs of postmenopausal osteoporotic mice [J]. BMC Complement Altern Med, 2015, 15: 250.
42 Nelson ER, Wardell SE, Mcdonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis [J]. Bone, 2013, 53(1): 42-50.
43 Xu XH, Dong SS, Guo Y, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: The 2009 Update [J]. Endocr Rev, 2010, 31(4): 447-505.
44 Liu YZ, Liu YJ, Recker RR, et al. Molecular studies of identification of genes for osteoporosis: The 2002 update [J]. J Endocrinol, 2003, 177(2): 147-196.
45 Liu YJ, Shen H, Xiao P, et al. Molecular Genetic Studies of Gene Identification for Osteoporosis: a 2004 Update [J]. J Bone Miner Res, 2006, 21(10):1511-1535.


[1]李博 李计东 刘丽君 曲磊 刘丽霞 贾媛媛 王海红 刘军.腓骨近端截骨术与口服药物治疗膝关节骨关节炎的对比研究[J].中华老年骨科与康复电子杂志,2016,(01):32.[doi:10.3877/cma.j.issn.2096-0263.2016.01.007]
 Li Bo,Li Jidong,Liu Lijun,et al.Therapeutic effect analysis of proximal fibular osteotomy for the treatment of patients withknee osteoarthritis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(06):32.[doi:10.3877/cma.j.issn.2096-0263.2016.01.007]
 Ma Xiaolong,Liu Qiang,Wu Dou,et al.Experimental study of osteoporotic microsurgery fractures in the early development process[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(06):129.[doi:10.3877/cma.j.issn.2096-0263.2016.03.001]
 Cui Hongwang,Jiang Dianming.Effect of the programmed cell death of osteocyte on osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2016,(06):181.[doi:10.3877/cma.j.issn.2096-0263.2016.03.011]
 Li Ziyi,Li Yukun.Researching progress and application of OPG-RANK-RANKL signaling pathway in osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):124.[doi:10.3877/cma.j.issn.2096-0263.2017.02.012]
 Lei Tao,Shen Yong..A brief discussion of osteoporotic vertebral fractures in elderly patients[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):248.[doi:10.3877/cma.j.issn.2096-0263.2017.04.010]
 Ma Shuwei.Clinical efficacy of percutaneous kyphoplasty in the treatment of acute and subacute phase of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):341.[doi:10.3877/cma.j.issn.2096-0263.2017.06.005]
 Liu Wei,Fu Guangtao,Hu Xumin,et al.Analysis in postmenopausal osteoporosis patients with fragility fracture during zoledronic acid treatment[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2017,(06):351.[doi:10.3877/cma.j.issn.2096-0263.2017.06.007]
 Bisphosphonates and atypical femur fractures femur[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):118.[doi:10.3877/cma.j.issn.2096-0263.2018.02.010]
 Liang Wei,Wu Dou,Zhao Enzhe,et al.Application research of Cortical thickness in osteoporotic hip fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):184.[doi:10.3877/cma.j.issn.2096-0263.2018.03.012]
 Xie Yaming,Xie Guosheng,Lin Meng,et al.Early clinical outcome of vesselplasty and kyphoplasty in treatment of osteoporotic vertebral compression fractures[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2018,(06):202.[doi:10.3877/cma.j.issn.2096-0263.2018.04.003]
 Wang Jianhua.Classification and selection of drugs for treating osteoporosis[J].Chin J Geriatr Orthop Rehabil(Electronic Edition),2019,(06):297.[doi:10.3877/cma.j.issn.2096-0263.2019.05.010]

更新日期/Last Update: 2019-12-12